Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

August 31, 2006

Conditions
Atrial Fibrillation
Interventions
DRUG

Vernakalant (oral)

DRUG

Placebo comparator

Trial Locations (22)

2000

Kardiologisk/endokrinologisk afd. E Frederiksberg Hospital, Frederiksberg

2730

KAS Herlev, Herlev

4600

Roskilde Amts Sygehus Koge, Køge

6000

Medicinsk Afdeling Kolding Sygehus, Kolding

8000

Aarhus Sygehus Kardiologisk Afd. A, Aarhus

9100

Aalborg Sygehus Syd, Aalborg

9800

Sygehus Vendsyssel Hjorring, Hjørring

17033

Penn State Heart & Vascular Institute, Hershey

35801

The Heart Center, P.C., Huntsville

54449

Marshfield Clinic, Marshfield

94598

Cardiovascular Consultants Medical Group, Inc., Walnut Creek

T2N 2T9

Foothills Hospital, Calgary

H2W 1T8

Centre Hospitalier de l'Université de Montréal (CHUM) Hôtel Dieu, Montreal

Unknown

Bispebjerg Hospital, Copenhagen

KAS Gentofte Kardiologisk Afdeling, Hellerup

Reinier de Graaf Gasthuis, Delft

Catharina Ziekenhuis, Eindhoven

Medisch Spectrum Twente, Enschede

University Medical Center Groningen (UMCG), Groningen

Trial sectie Cardiologie, Heerlen

Academisch Ziekenhuis Maastricht, Maastricht

Stichting Sint Antonius Ziekenhuis, Nieuwegein

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Advanz Pharma

INDUSTRY

NCT00267930 - Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence | Biotech Hunter | Biotech Hunter